Arcturus Therapeutics Holdings Inc. (ARCT) stock plummeted 23.48% in the current-market trading session at the price of $19.33 after publishing topline results from its Phase 1/2/3 clinical trial that evaluates ARCT-154.
ARCT-154 Met Primary Endpoints
On 20th April 2022, ARCT published topline results from its Phase 1/2/3 clinical trial assessing ARCT-154, an mRNA vaccine treating Covid-19 infection. The ongoing clinical study, conducted by Vinbiocare, registered nineteen thousand adult patients in Vietnam with a greater risk of Covid-19 complications. Vinbiocare has already submitted the efficacy results of the study to the Vietnam Health Ministry on 13th April 2022 and shared them with ARCT.
The Phase-III placebo-controlled vaccine efficacy analysis of this study registered sixteen thousand individuals. Investigations of vaccine efficacy confirmed that the study met its primary endpoint of deterrence from the Covid-19 virus. Additionally, the secondary endpoints of Covid-19 conditions have been analyzed including 43 chronic cases. Forty-one cases indicated a vaccine efficacy estimate point of 95 percent against intense Covid-19 symptoms. Nine Covid-19-based deaths had also reported in the placebo group of the study.
ARCT, located in San Diego, is a clinical-stage mRNA pharmaceutical firm that leverages its proprietary LUNAR and STARR technologies to produce medicines and vaccines. Arcturus’ RNA therapeutics approach can be applied to numerous nucleic acid drugs, including mRNA and gene editing medications. The stock’s pipeline of RNA therapeutics and vaccine candidates includes mRNA vaccine for Covid-19 and other programs to treat cystic fibrosis and OTC deficiency.
ARCT Market Updates
ARCT stock is working on EUA for emergency use authorization of ARCT-154 across Vietnam. ARCT-154 proved to be well-tolerated and safe based on the review and results of blinded data from clinical trials. The filing had based on safety, efficacy, and immunogenicity results from the Phase 1/2/3 clinical study. The stock is engaging several other authorities to clear the path of drug approval.